Rosen Law Firm Urges MoonLake Immunotherapeutics Investors to Act Before December 15 Deadline

Rosen Law Firm, a global investor‑rights firm, is reminding anyone who purchased common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025 (inclusive) that they may be eligible to participate in a securities class action — provided they act by the important deadline of December 15, 2025. Key points: If you bought MoonLake common stock during the class period, you might be able to recover damages without paying out‑of‑pocket fees, thanks to a contingency‑fee arrangement. To join the class or move to become lead plaintiff, investors must act promptly: the lead‑plaintiff motion must be filed by December 15. The lawsuit alleges that MoonLake made false or misleading statements about the clinical benefits of its “Nanobody” therapy compared to traditional monoclonal antibodies — specifically, that the company overstated claims of superiority in molecular targeting and clinical tissue penetration without a reasonable basis. Rosen emphasizes the importance of choosing experienced counsel rather than relying on firms that simply refer clients to litigators; Rosen highlights its own track record in securities class actions and investor recoveries. If you believe you fall within the class period, Rosen encourages you to submit a form online or contact their office by phone or email to explore your rights. #MoonLake #SecuritiesClassAction #InvestorRights #RosenLawFirm #SlimScan #GrowthStocks #CANSLIM